Q: Is ANP currently available to me?
A: ANP is not currently available from the Burzynski Clinic. The IND (Investigational New Drug) which Burzynski Research Institute, Inc. (BRI) owns is under an FDA partial clinical hold which under a hold as well. The Clinic can only treat current patients and may not accrue any new ones until the hold is lifted.
Q: Can I get ANP abroad?
A: Not at this time; the FDA also regulates BRI’s ability to export ANP.
Q: Is there any other way for me to get ANP?
A: Yes. The FDA states that they have an “Expanded Access” for Investigational New Drugs on a compassionate use basis. Anyone with a terminal diagnosis should qualify. You may contact us for advice, but regardless, always involve your Senators and Congressional Representative. This can be a very complex bureaucratic process! (See the “Treatment Information” button on our Home page.)
Q: What types of cancers has ANP shown some/any level of efficacy on?
A: The ANP Coalition has had personal contact with patients on ANP who have medically confirmed efficacy ranging from reduction in tumors to complete responses in the types of cancer listed. (See the “Treatment Information” button on our Home page.)
Q: Has ANP shown efficacy on any illnesses or diseases other than cancer?
A: In the early 1980s and 1990s, studies showed benefit in the following diseases: HIV, Lupus, Multiple Sclerosis, and autoimmune diseases.
Q: Can other doctors obtain ANP from the Burzynski Clinic and administer it?
A: Yes, if the FDA is sincere in their Expanded Access policy stated above.
A: Yes. An independent randomized clinical study has been completed. That study is pending peer review publishing. The authors have no control over the timetable involved. The abstract of the clinical study done by the Japanese doctors has been published. Portions, excerpts and case studies have been published. Refer to our “ANP Links” button and the “ANP Publications” page.
Q: Has ANP been identified and published in “peer-reviewed” data/Journals?
A: Yes, it has. Please note our “ANP Links” button and the “ANP Publications” page.
Q: Are the completed ANP Phase II Clinical studies published in Peer Review Journals?
A: Yes. Portions, excerpts and case studies have been published. The publication of several complete FDA Phase II clinical studies is currently pending Peer Journal review. So is a completed independent randomized clinical study. The authors of these studies have no control over when the studies will be published.
Q: Does the National Cancer Institute (NCI) acknowledge the clinical efficacy of antineoplastons today?
A: Yes. You can visit their website via our “ANP Links” button and the “ANP Publications” page.
Q: How do I know if ANP is an appropriate treatment modality for me?
A: Invariably you will have to consult with the Burzynski Clinic to determine what, if any benefit you might derive from ANP.
Q: Does ANP work for everybody?
A: Cancer is a very complex group of numerous diseases. ANP does not work for everyone; it does work for some patients with some types of cancer.
Q: What is being done to pursue the efficacy of ANP?
A: At this point, Clinical trials and research have been limited to private institutions. No (significant) government resources have been used to assist in the research and development of ANP. ANP are in their infancy in terms of overall research.
Q: Will genetic testing help determine whether or not ANP will work for me?
A: It is not necessary to perform genetic testing because ANP covers over 100 genes.
Q: What are the ingredients in antineoplastons (ANP)?
A: The chemicals that are used to enable your body to produce the peptides that comprise the active ingredients for Dr. Stanislaw Burzynski’s patented antineoplastons are:
*Antineoplaston AS2-1: Phenylacetylglutamineate sodium and Phenylacetatesodium
*Antineoplaston A10: Phenylacetylisoglutaminate sodium
Q: How do I choose a cancer treatment modality?
A: The wisest way to select any medical treatment is to compare efficacy vs. toxicity. Ideally, you want the treatment most likely to produce a complete response (cure) with the mildest possible side effects. List your potential modalities comparatively using this criterion. Everything else is peripheral to these two main factors, and should only be used in the selection process if two modalities are exactly comparable.
Q: Will insurance pay for my ANP treatment?
A: According to the Burzynski Clinic, they offer ANP formulations free-of-charge to patients participating in clinical trials and under compassionate exception.
Q: Where are antineoplastons made?
A: ANP are produced in a 46,000 square foot pharmaceutical manufacturing facility in Stafford Texas. This facility is inspected periodically by the FDA, EPA and other regulatory agencies.
Q: How much does ANP cost?
A: ANP formulation is a complex manufacturing process which involves a number of expensive precursors. The Burzynski Clinic uses a price structure that actually charges for the service rather that the medication itself. Ultimately, you will need to consult with the Clinic to determine your needs and the actual expense of treatment. The ANP formulations are provided free-of-charge to patients participating in clinical trials and under compassionate exception.
Q: How long has ANP been around?
A: ANP were first discovered by Dr. Stanislaw Burzynski in 1967. They were first proposed as a possible cancer treatment in 1976, and have been used in humans with positive results since then.
Q: Where do ANP come from?
A: ANP were originally isolated from human blood and urine, but are now synthesized from chemicals in the developer’s pharmaceutical laboratory.
Q: Have any independent randomized controlled Studies been done?
A: Japanese scientists have recently completed 27 years of independently conducted clinical trials, including a randomized study with 65 patients for colon cancer metastasized to the liver. These independent studies have been submitted for international medical journal publication and are pending publication.
Q: What are antineoplastons?
A: Antineoplastons are a group of chemical compounds that are normally found in blood and urine. They are made up mostly of amino acids (the building blocks of protein) and peptides (compounds made of two or more amino acids). For use in medical research, antineoplastons were originally taken from human urine, but they are now produced synthetically from chemicals in the laboratory.
Q: How does ANP work?
A: ANP activates tumor suppressor-genes which kill cancer cells, and turn off oncogenes which stimulate the growth of cancer.
Q: Will my treatment be administered by a doctor?
A: Usually, a new patient receives initial training and several weeks’ worth of monitoring at the Burzynski Clinic. Then the patient returns home for periodical monitoring by their local physician. Normally this is all done on an outpatient basis. Generally ANP is self-administered by the patient (or caregiver).
Q: How are antineoplastons administered?
A: Antineoplastons are generally administered intravenously through an injection pump which is self-administered by the patient.
Q: Is ANP toxic?
A: Yes, ANP has a benign toxicity. There are no long-term toxic side effects.
Q: How does the toxicity of ANP compare to “conventional” cancer treatments?
A: ANP does not have any known long-term toxic side effects such as common cancer treatments do. ANP works on a completely different principle so the mechanics of other treatments are not comparable to ANP. (Refer to our “ANP Links” button and the “What is ANP?” page.)
Q: Have any side effects or risks been reported from antineoplastons?
A: Antineoplastons include short-term side effects:
- Anemia (lower than normal number of red blood cells)
- High blood pressure
- Fever and chills
- Feeling very tired
- Abnormal levels of calcium in the blood
- High sodium levels in the blood
- Low potassium levels in the blood
- Dry or itchy skin rash
- Nausea and vomiting
- Irregular heartbeat
- Swelling caused by excess fluid in body tissues
- Swelling, pain, or stiffness in small joints
- Frequent urination